MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.
You may also be interested in...
AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.